# A Randomized Study To Evaluate Efficacy And Safety Of A Fixed Combination Therapy Of Amlodipine And Atorvastatin

> **NCT00530946** · PHASE3 · COMPLETED · sponsor: **Pfizer's Upjohn has merged with Mylan to form Viatris Inc.** · enrollment: 165 (actual)

## Conditions studied

- Hypertension
- Hypercholesterolemia

## Interventions

- **DRUG:** Amlodipine 2.5mg/Atorvastatin 5mg
- **DRUG:** Amlodipine 2.5mg/Atorvastatin 10mg
- **DRUG:** Amlodipine 5mg/Atorvastatin 5mg
- **DRUG:** Amlodipine 5mg/Atorvastatin 10mg

## Key facts

- **NCT ID:** NCT00530946
- **Lead sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2008-04
- **Final completion:** 2008-04
- **Target enrollment:** 165 (ACTUAL)
- **Last updated:** 2021-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00530946

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00530946, "A Randomized Study To Evaluate Efficacy And Safety Of A Fixed Combination Therapy Of Amlodipine And Atorvastatin". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00530946. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*